Catalent Appoints Paul Hegwood as New President of Clinical Supply Services

SOMERSET, N.J., June 13, 2018 /PRNewswire-PRWeb/ -- Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has appointed Mr. Paul Hegwood as President of the company's Clinical Supply Services business. He succeeds Mr. Wetteny Joseph, who was named as Catalent's Chief Financial Officer in February 2018.

Mr. Hegwood has been with Catalent for the last seven years in various leadership roles, most recently acting as Global Vice President of Clinical Supply Services Operations. He was previously Vice President of Global Operational Excellence and joined the company following an extensive career leading multi-national teams in operations, business development and engineering. He holds an MBA from the University of Michigan and a bachelor's degree in mechanical engineering from Kettering University, Michigan. Mr. Hegwood is a trained specialist in Lean Manufacturing and is a certified Six Sigma Green Belt.

"Paul has been one of the most vocal and passionate champions of embedding 'Patient First' into Catalent's culture," commented John Chiminski, Catalent's Chair and CEO. He added, "Paul is a builder of strong teams, and his excellent track record of strengthening customer relationships will drive excellence in the business."

With eight sites in the U.S., U.K., Germany, Japan, Singapore and China, and an extended network of over 50 depots covering six continents, Catalent's clinical supply services team has the capability and expertise to handle a broad range of international compliance and distribution requirements, and help to expedite clinical trials Phases 1-4 by ensuring customers are reliably supplied where and when needed around the globe.

For further information on Catalent's Clinical Supply Services business visit catalent.com/clinical.

About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 11,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2017 generated over $2 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.(TM)

SOURCE Catalent, Inc.